Key Figures Q1 2020

SEK m, unless otherwise stated

2020

Jan-Mar

2019

Jan-Mar

2019

Jan-Dec

Δ

2019-2020

Net revenues

175.0

174.3

844.8

0.4%

Cost of goods sold

-20.0

-25.3

-105.6

-21%

Operating expenses

-121.1

-147.9

-508.0

-18%

EBIT

34.0

1.1

231.2

2991%

EBIT margin, %

19.4

0.6

27.4

18.8 ppt

EBITDA

39.1

12.0

272.1

226%

Earnings per share, before dilution, SEK

2.38

0.41

6.33

483%

Earnings per share, after dilution, SEK

2.34

0.40

6.20

484%

Cash flow from operating activities

48.1

50.9

287.0

-5.6%

Cash and cash equivalents

861.4

647.4

816.8

33%

Net revenues and EBIT per segment Q1 2020

SEK m

Net Revenues

EBIT

 

2020

Jan-Mar

2019

Jan-Mar

2019

Jan-Dec

2020

Jan-Mar

2019

Jan-Mar

2019

Jan-Dec

Zubsolv® US

163.9

161.7

719.2

75.9

68.2

347.1

US Pharma – total

163.9

161.7

719.2

75.9

68.2

347.1

Digital Therapeutics

-

-

-

-12.1

-

-0.9

Digital Therapeutics– total

-

-

-

-12.1

-

-0.9

Abstral® royalties

8.6

10.9

112.6

-

-

-

Edluar® royalties

2.4

1.7

11.6

-

-

-

Zubsolv - ex US

0.1

0.0

0.1

-

-

-

OX-MPI

-

-

1.4

-

-

-

HQ & Pipeline segment – total

11.1

12.6

125.6

-29.9

-67.1

-115.0

Total

175.0

174.3

844.8

34.0

1.1

231.2

Cash flow Q1 2020

SEK m

Q1

2020

Q1
2019

Jan - Dec

2019

Cash flow from operating activities

48.1

50.9

287.0

Investment activities

-3.9

-0.1

-22.4

Financing activities

-68.8

-10.7

-53.7

Cash flow (excl exchange rate differences)

-24.6

40.2

210.8

Liquid funds

861.4

647.4

816.8